Search

Displaying results 2251 - 2260 of 7059 in total
  1. Drug

    Laroprovstat

    go.drugbank.com/drugs/DB21690
    Investigational

    Laroprovstat is a small molecule drug. Laroprovstat has a monoisotopic molecular weight of 414.16 Da.

  2. Drug

    Evategrel

    go.drugbank.com/drugs/DB21691
    Experimental

    Evategrel is a small molecule drug. Evategrel has a monoisotopic molecular weight of 471.11 Da.

  3. Drug

    Lecufexor

    go.drugbank.com/drugs/DB21714
    Experimental

    Lecufexor is a small molecule drug. Lecufexor has a monoisotopic molecular weight of 618.05 Da.

  4. Drug

    Matsupexole

    go.drugbank.com/drugs/DB21715
    Experimental

    Matsupexole is a small molecule drug. Matsupexole has a monoisotopic molecular weight of 446.25 Da.

  5. Drug

    Balinatunfib

    go.drugbank.com/drugs/DB21728
    Investigational

    Balinatunfib is a small molecule drug. Balinatunfib has a monoisotopic molecular weight of 502.19 Da.

  6. Drug

    Rogocekib

    go.drugbank.com/drugs/DB21739
    Investigational

    Rogocekib is a small molecule drug. Rogocekib has a monoisotopic molecular weight of 408.15 Da.

  7. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. … Patients are advised to immediately contact their healthcare provider if a rash develops.

  8. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

  9. Drug

    Clopenthixol

    go.drugbank.com/drugs/DB13841
    Investigational

    Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

  10. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).